Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 15/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.50 |
| ▸ | USP2 | O75604 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 11/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930489 | 0.92 | KDM4C (0.53) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL2233967 | 0.87 | AURKA (0.47) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL30402747 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL15542062 | 0.84 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL9930862 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL24399750 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL15542246 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL10251198 | 0.82 | AURKA (0.43) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL10285594 | 0.82 | L3MBTL1 (0.45) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 | |
| SCHEMBL29921676 | 0.82 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4238967-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| EP-4238967-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022089219-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP1A2 2189/4885CYP3A4 2785/4885CYP2C19 2795/4885 |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | AHR, ARNT, NOTUM | CYP1A2 49/4885CYP3A4 91/4885CYP2C19 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.